Clinically, breast cancer is classified into three major subtypes: hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−), HER2− positive (HER2+; defined by gene amplification or receptor overexpression), and triple-negative (HR−/HER2−). This evidence concerns the gene ERBB2 and breast cancer.